The Team’s fundamental premise was that improving early detection of invasive lung cancers is a solvable technological problem that can be immediately linked to a definitive clinical treatment. The Team built a test, called the Lung Cancer Interception Assay, as a composite blood-based biomarker assay that could be used in conjunction with standard imaging.